Literature DB >> 11550124

Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver.

J Boisvert1, X S He, R Cheung, E B Keeffe, T Wright, H B Greenberg.   

Abstract

Prior studies seeking evidence of viral replication in peripheral lymphocytes of hepatitis C virus (HCV)-infected patients have yielded conflicting results. This study sought to quantitatively determine whether a permissive HCV cell interaction could be detected in leukocytes from infected patients. Peripheral leukocytes from chronically infected patients were purified and were tested for HCV RNA. The results show that virus load is highest in B cells. Other subsets of peripheral leukocytes consistently had very low levels of viral RNA or were negative. Negative-strand HCV was found only in hepatocytes. To determine whether HCV replication could be induced by activation, B cells from HCV-infected patients were stimulated in vitro. No HCV replicating in peripheral leukocytes was detected by a highly sensitive assay. If HCV replication occurs in the leukocyte subsets analyzed here, it is at extremely low levels or occurs under alternate physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550124     DOI: 10.1086/323391

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

2.  Does occult hepatitis C virus infection exist?

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  J Clin Microbiol       Date:  2008-10       Impact factor: 5.948

3.  Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.

Authors:  Claire Bertaux; Tatjana Dragic
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system.

Authors:  Richard Y Wang; Patricia Bare; Valeria De Giorgi; Kentaro Matsuura; Kazi Abdus Salam; Teresa Grandinetti; Cathy Schechterly; Harvey J Alter
Journal:  Hepatology       Date:  2016-10-24       Impact factor: 17.425

5.  Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients.

Authors:  Ian Gaël Rodrigue-Gervais; Loubna Jouan; Geneviève Beaulé; Dominike Sauvé; Julie Bruneau; Bernard Willems; Rafick-Pierre Sékaly; Daniel Lamarre
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.

Authors:  Lisa Cukierman; Laurent Meertens; Claire Bertaux; Francis Kajumo; Tatjana Dragic
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 7.  Pathogenic interactions between alcohol and hepatitis C.

Authors:  Gyongyi Szabo
Journal:  Curr Gastroenterol Rep       Date:  2003-02

8.  Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells.

Authors:  Qing Zhu; Ju-Tao Guo; Christoph Seeger
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection.

Authors:  Jason T Blackard; Yoichi Hiasa; Laura Smeaton; Denise J Jamieson; Irma Rodriguez; Kenneth H Mayer; Raymond T Chung
Journal:  J Infect Dis       Date:  2007-05-02       Impact factor: 5.226

10.  L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Authors:  Emmanuel G Cormier; Robert J Durso; Fotini Tsamis; Lise Boussemart; Catherine Manix; William C Olson; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.